Atlas Trials

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.

Clinical trial NCT05279313 · COMPLETED

Trial details

NCT number
NCT05279313
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Attention Deficit/Hyperactivity Disorder
Start date
2022-02-24
Primary completion
2026-04-24
Enrollment
680

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.